Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)

• Status: Completed
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the value of induction Erlotinib therapy before thoracotomy or radiotherapy in ⅢA-N2 (confirmed by mediastinoscopy or PET) non-small cell lung cancer (NSCLC) selected by epidermal growth factor receptor (EGFR) gene analysis and initial to explore a new treatment strategy for ⅢA-N2 NSCLC.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guangdong Provincial People's Hospital
• Treatments: Carboplatin; Erlotinib Hydrochloride; Gemcitabine

Criteria

Inclusion Criteria:

• Written informed consent

• Histological or cytological documented

• Resectable NSCLC of stage IIIA-N2 confirmed by mediastinoscopy or PET

• Naive therapy NSCLC

• Candidates should be tolerated with induction therapy and thoracotomy with ECOG performance status 0-2, adequate haematological and Hepatic- renal function and qualified lung function

• Enough tissue samples to perform gene analysis

Exclusion Criteria:

• Small cell lung cancer

• Pregnant or breast-feeding women

• Any unstable systemic disease

• Patients with exposure to investigational drug therapy or other concurrent anticancer therapy outside of this trial